Summary
Explore the Biden Administration’s draft proposal on “march-in” rights for patented drugs, aiming to license drugs developed with taxpayer funds if not reasonably priced for Americans. The proposal, currently under agency evaluation, raises concerns about defining “reasonable” pricing and potential impacts on drug availability and safety.
Did you find this helpful?
Thank you for your feedback!
Posted in Technology, Uncategorized
